The Oncology Brothers, Dr. Wallis Give Their Thoughts on PROpel, TALAPRO-2, and EV-103 Cohort K

By Oncology Brothers, Christopher Wallis, MD, PhD, FRCSC - Last Updated: June 5, 2023

The Oncology Brothers—Rahul Gosain, MD, Wilmot Cancer Institute at Webster, and Rohit Gosain, MD, UPMC Hillman Cancer Center—chat with Christopher Wallis, MD, PhD, University of Toronto, on the ASCO research presented in PARP inhibitors for GU cancers, as well as neoadjuvant immunotherapy and enfortumab vedotin for bladder cancer.

View more ASCO 2023 videos.

Real-world Association of Tumor-Informed MRD With Clinical Outcomes for MIBC

Ajitha Kommalapati, MDASCO 2023 | August 15, 2023

Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC.

Drs. Gupta, Koshkin on EV-103 Cohort K Results and Toxicities

Shilpa Gupta, MDASCO 2023 | August 4, 2023

Drs. Shilpa Gupta and Vadim Koshkin continue on the EV-103 trial with reference to outcomes and toxicities in cohort K.

Drs. Gupta, Koshkin on EV-103 Design and Long-term Cohort A Results for Patients With aUC

Shilpa Gupta, MDASCO 2023 | August 4, 2023

Drs. Shilpa Gupta and Vadim Koshkin discuss the EV-103 trial and data, including long-term results for cohort A.

Biomarkers of Response to SG and EV in Advanced Urothelial Carcinoma: Analysis of the UNITE Study

Tanya JindalASCO 2023 | July 28, 2023

Tanya Jindal expands upon the UNITE study findings relative to biomarkers of response for SG and EV for advanced UC.

Dr. Thomas Hutson on Long-Term Durable Response After 4 Years Follow-Up in the CLEAR Study

Thomas Hutson, DO, PharmD, FACPASCO 2023 | July 17, 2023

Dr. Hutson details the latest 4-year CLEAR data for patients who received 1L lenvatinib plus pembrolizumab for advanced RCC.

The Oncology Brothers, Dr. Wallis Give Their Thoughts on PROpel, TALAPRO-2, and EV-103 Cohort K

Related Posts